TCT-848 Percutaneous coronary intervention with Absorb bioresorbable vascular scaffold: major adverse cardiac events, restenosis and device thrombosis after 2-years follow-up. Single center experience in an all-comers population

• Published in: Journal of the American College of Cardiology Vol. 70; no. 18; pp. B342 - B343
• Main Authors: De Miguel Castro, Antonio, Hernandez, Etelberto, Diaz, Victor Jimenez, Saez, Alberto Ortiz, Fernández, Guillermo Bastos, Barbeira, Saleta Fernández, Gomez-Blazquez, Ivan, Baz, Jose, Iñiguez, Andres
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 31-10-2017; Elsevier Limited
• Subjects: Angina pectoris; Angioplasty; Biocompatibility; Biomedical materials; Cardiology; Clinical medicine; Clinical trials; Electrocardiography; Heart attacks; Heart diseases; Restenosis; Stents; Stroke; Surgical implants; Thromboembolism; Thrombosis
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2017.09.1056

Characteristics of the patients at baseline: mean age 58,5 years, male 78,7%, hypertension 54,5%, dyslipidemia 68,8%, diabetes mellitus 26,2%, previous myocardial infarction 25,5%, previous percutaneous coronary intervention 41,1%, previous bypass surgery 3,5%, mean ejection fraction 56,35%. Stents: Bioresorbable Vascular Scaffolds Clinical events after 2 years follow-up Composite of cardiac death, myocardial infarction or stroke 11 (5,5%) Death from any cause - Cardiac 9 (4,5%) 5 (2,5%) Stroke - Ischemic - Hemorrhagic 2 (1,0%) 1 (0,5%) 1 (0,5%) All myocardial infarction - Non Q-wave - Q-wave - Fatal 6 (3,0%) 3 (1,5%) 3 (1,5%) 1 (0,5%) Definitive scaffold thrombosis 6 (3,0%) Restenosis 14 (7,0%)